Thrombocytosis and Your Skin: What to Look For

Thrombocytosis, a condition in which the body produces too many platelets, can leave visible traces on your skin long before blood work reveals the problem. The most recognizable sign is erythromelalgia, a painful reddening of the fingers or toes that affects roughly 6% of people with essential thrombocythemia, the most common form of clonal thrombocytosis. But skin involvement goes well beyond red extremities. Itching, color changes in the hands and feet, and even non-healing ulcers can all be connected to an abnormally high platelet count, whether the cause is a bone marrow disorder or the treatment used to manage it.

Erythromelalgia, the Most Distinctive Skin Sign

If there is one skin change that doctors associate specifically with thrombocytosis, it is erythromelalgia. The condition presents as episodes of redness, warmth, and burning pain, usually in the toes or fingers, though the soles of the feet and palms of the hands can be affected too. During a flare the skin looks flushed or even dusky red, and the affected area feels hot to the touch. Many people describe the sensation as standing on a hot griddle. The episodes can last minutes to hours and are often triggered by warmth, exercise, or simply standing for a while.¹

What makes erythromelalgia in thrombocytosis different from other causes of the same symptom is how it happens at the microscopic level. Research spanning more than two decades has shown that the problem is driven by activated platelets clumping inside the tiny arteries of the skin. These platelet-rich clots partially block blood flow in the fingers and toes, triggering the characteristic burning and redness.² Laboratory work confirms this picture: compared with patients who have thrombocytosis but no erythromelalgia, those experiencing the burning episodes show higher levels of beta-thromboglobulin (a marker of platelet activation) and thrombomodulin (a marker of blood-vessel-lining damage). Notably, traditional blood thinners like warfarin and heparin don’t help, because the tiny clots are held together by platelet-to-platelet sticking rather than the fibrin meshwork those drugs target.³

The practical takeaway is straightforward: low-dose aspirin is the treatment of choice, and the response is so reliable that it serves as a diagnostic clue. If a person with a high platelet count develops burning red toes and the symptoms melt away within hours of taking aspirin, that pattern strongly supports the diagnosis of thrombocythemic erythromelalgia.⁴ The relief typically lasts for days on a single dose, which is unusual for a simple pain reliever and reflects the fact that aspirin is actually shutting down the platelet activation driving the problem, not just masking discomfort.

Itching That Won’t Quit

Persistent itching is the single most commonly reported skin symptom among people with essential thrombocythemia, though estimates of how many people experience it vary widely, from as few as 3% to nearly half depending on how it is measured.⁵ The itch tends to be generalized rather than localized to one spot, and in the closely related condition polycythemia vera it is famously triggered by contact with warm water (the so-called “aquagenic pruritus” that makes hot showers miserable). In thrombocytosis, the mechanism appears to involve platelet-derived substances acting on nerve endings in the skin. Research on polycythemia vera patients found that platelets release compounds like prostaglandin E2 and serotonin, both of which can provoke itching when injected into the skin of healthy volunteers, and that prostaglandin E2 amplifies the skin’s response to serotonin.⁶

This kind of itch is frustrating because the skin itself often looks perfectly normal. There is no rash, no hives, no visible cause. Standard antihistamines frequently disappoint, because the itch is being driven by platelet chemistry rather than the classic histamine pathway. Aspirin helps some people, presumably by reducing the production of prostaglandins by platelets, but the results are inconsistent. If you have been living with an unexplained, treatment-resistant itch and your blood counts happen to be elevated, the itching may be worth mentioning to your hematologist rather than your dermatologist.

Color Changes in the Hands and Feet

Beyond erythromelalgia and itching, thrombocytosis can cause several other visible changes in the skin of the extremities. These are less common individually but collectively they paint a recognizable picture of compromised microcirculation:

Livedo reticularis: A lace-like or net-like purplish discoloration of the skin, most often on the legs. It results from sluggish blood flow through the small vessels of the skin and can look alarming, though it is not always painful.
Acrocyanosis: Persistent bluish discoloration of the fingers or toes, sometimes with a cool or clammy feel. Unlike Raynaud’s phenomenon, it tends to be constant rather than episodic.
Raynaud’s phenomenon: Episodes in which the fingers or toes turn white, then blue, then red in response to cold or stress. This is common in the general population for other reasons, but when it appears alongside a high platelet count, the connection is worth investigating.

All three of these signs are considered rare manifestations of essential thrombocythemia.⁵ They share a common thread with erythromelalgia: excessive platelet activation gumming up the smallest blood vessels. The key difference is one of degree. Erythromelalgia involves active pain and warmth; livedo reticularis and acrocyanosis are more about sluggish flow producing visible discoloration without the intense burning. If you notice new purple netting on your calves or blue-tinged fingertips that weren’t there before, especially alongside other symptoms like fatigue or headaches, these could be clues pointing toward a blood count problem.

When Skin Changes Signal an Emergency

Most skin signs of thrombocytosis are uncomfortable but not dangerous. The exception is digital ischemia, where platelet-driven clots reduce blood flow to a finger or toe so severely that the tissue starts to die. A case report described a patient whose first indication of essential thrombocythemia was gangrene of the toes, presenting with blackened, painful tissue at the tips of the feet.⁷ In that context, the skin change isn’t a nuisance; it is a surgical emergency.

Certain factors raise the odds of these serious vascular complications. Being 60 or older, having a platelet count above 450,000 per microliter, having a white blood cell count above 11,000, or having a prior history of blood clots all push a person into a higher-risk category.⁷ For someone already diagnosed with thrombocytosis, the appearance of a toe or finger that becomes persistently pale, then blue or black, should not be attributed to cold weather or tight shoes. It needs urgent medical evaluation, because the window for saving the tissue is narrow once blood flow has been cut off.

There is also a subtle warning pattern to watch for. Erythromelalgia, if left untreated, can progress: the burning episodes become longer, the redness deeper, and eventually the tissue at the tips of the toes can begin to break down. What starts as a reversible microvascular problem can slowly evolve into an irreversible one. Low-dose aspirin, as noted earlier, interrupts this process in most cases. But if the burning episodes are becoming more frequent or harder to control with aspirin, that change in pattern is worth reporting promptly.

Skin Problems Caused by Treatment

One of the less intuitive aspects of thrombocytosis and skin is that the medications used to lower the platelet count can themselves cause skin problems, sometimes quite severe ones. Hydroxyurea (also known as hydroxycarbamide) is the most widely used cytoreductive drug for essential thrombocythemia, and it carries a well-documented risk of painful leg ulcers. These ulcers typically develop on the lower legs or ankles, often after years of therapy, and they resist standard wound care.⁸ They can recur even after surgical repair, sometimes breaking open again at the same site within months.⁹

The mechanism behind hydroxyurea-induced ulcers is not entirely settled, but the drug is thought to impair the skin’s ability to repair itself by slowing cell division in the rapidly turning-over layers of the epidermis and the cells lining small blood vessels. Other skin side effects of hydroxyurea include hair thinning, darkening of the skin and nails, and the development of precancerous sun-damage spots known as actinic keratoses. If you are on long-term hydroxyurea therapy, routine skin checks become more important than they might otherwise be.

Hydroxyurea is not the only culprit. Interferon-alfa, another treatment used especially in younger patients or those who cannot tolerate hydroxyurea, has been linked to dry skin, itching, and sun sensitivity. Anagrelide, a drug that specifically targets platelet production, appears to have fewer skin side effects, with problems documented mainly in isolated case reports.⁵ The practical point here is that not every skin change in someone with thrombocytosis is caused by the disease itself. If you develop a new skin symptom, especially a wound that won’t heal or unusual dryness and sensitivity, your treatment may be the explanation.

How to Tell Disease-Related Skin Changes From Treatment Side Effects

This is one of the genuinely tricky parts of living with thrombocytosis. You develop a skin issue and have to figure out whether it is the disease, the drug, or something completely unrelated. There is no single test that sorts this out, but a few patterns help.

Disease-driven skin problems tend to involve the fingers and toes, tend to be symmetrical, and tend to fluctuate with platelet count and activity level. They also tend to respond to aspirin. Treatment-driven skin problems tend to show up in different locations (lower legs for hydroxyurea ulcers, diffuse for interferon-related dryness), tend to develop gradually over months to years of therapy, and do not respond to aspirin. Hydroxyurea-associated ulcers in particular have a characteristic stubbornness to wound care that sets them apart from ulcers caused by venous insufficiency or diabetes.

If a skin change appeared shortly after starting a new medication or after a dose increase, timing alone is a strong clue. If it appeared alongside a spike in platelet count during an uncontrolled period, the disease is the more likely driver. In ambiguous cases, your hematologist may adjust treatment to see whether the skin improves, which essentially functions as a diagnostic test.

Reactive Thrombocytosis and Skin

Most of the discussion above applies to clonal thrombocytosis, the kind caused by a bone marrow disorder like essential thrombocythemia or polycythemia vera. But the majority of people with a high platelet count on a lab test have reactive thrombocytosis, meaning the platelets are elevated because of something else: an infection, iron deficiency, surgery, inflammation, or cancer elsewhere in the body. In reactive thrombocytosis, the platelets are generally not activated the way they are in clonal disease, so the risk of the microvascular skin complications discussed above is much lower.

There is an important exception. In Kawasaki disease, a condition that primarily affects young children and causes inflammation of blood vessel walls, thrombocytosis typically develops in the second to third week of illness. This was long considered a harmless side effect of the inflammatory process. More recent research, however, suggests that the platelets in Kawasaki disease are not just elevated but actively turned on, raising the risk of clot formation.¹⁰ Children with Kawasaki disease can develop skin peeling on the fingertips and toes, rashes, and redness of the palms and soles, though these are usually attributed to the underlying vasculitis rather than the elevated platelet count alone. The overlap between platelet activation and skin changes in Kawasaki disease is an area where the science is still catching up to clinical observation.

For adults with reactive thrombocytosis, skin changes like erythromelalgia are uncommon enough that if they do appear, the finding should prompt your doctor to reconsider whether the thrombocytosis is truly reactive or whether an underlying clonal disorder has been missed.

Thrombocytosis During Pregnancy

Pregnancy adds another layer of complexity for anyone managing thrombocytosis. Women with essential thrombocythemia face a significantly higher rate of miscarriage compared with the general population. In one study, about a third of pregnancies in women with essential thrombocythemia ended in miscarriage, versus roughly 8% in a control group. Composite pregnancy complications overall, including preeclampsia and growth restriction, were also substantially more common. Platelet counts above 1,000,000 per microliter were associated with even higher complication rates: roughly three-quarters of women whose pregnancies had complications had counts above that threshold, compared with a quarter of those with uncomplicated pregnancies.¹¹

What does this have to do with skin? The placenta is essentially a dense bed of small blood vessels, and the same platelet-driven microvascular problems that cause erythromelalgia in the toes can compromise blood flow through the placenta. For pregnant women with essential thrombocythemia, worsening of existing skin symptoms like erythromelalgia or new onset of livedo reticularis can be a sign that microcirculation is deteriorating generally, which may have implications beyond the skin. Any new or worsening vascular skin symptom during pregnancy should be flagged immediately, as it may reflect changes that also affect placental blood flow.

Minor Bleeding Into the Skin

It seems counterintuitive that a condition defined by too many platelets, the very cells responsible for forming clots, could cause bleeding. Yet minor skin bleeding such as easy bruising, pinpoint red dots (petechiae), and tiny dark lines under the nails (splinter hemorrhages) can occur in thrombocytosis. This happens because at extremely high platelet counts, the excess platelets can bind and consume a clotting protein called von Willebrand factor, paradoxically leaving the blood less able to form stable clots in some situations. The result is a condition called acquired von Willebrand syndrome, which is particularly associated with platelet counts above 1,000,000 per microliter.

Minor bleeding has been recognized as one of the skin manifestations of essential thrombocythemia.⁵ If you bruise easily or notice new petechiae, especially on the lower legs, it is worth getting a platelet count checked. And if you are already being monitored for thrombocytosis, new bruising could signal that your platelet count has climbed high enough to tip the balance from clotting risk to bleeding risk, which changes how aggressively you should use aspirin.

What a Skin Check Should Include

If you have been diagnosed with thrombocytosis, or if you are being monitored because of persistently elevated platelet counts, keeping an eye on your skin is a low-effort, high-value habit. You do not need specialized equipment or a dermatology appointment for routine self-monitoring. Here is what to pay attention to:

Fingers and toes: Look for redness, bluish discoloration, or areas that turn white and then red with temperature changes. Feel for warmth or coolness compared with the surrounding skin. Track whether burning episodes are becoming more frequent or lasting longer.
Lower legs and ankles: Watch for purplish net-like patterns (livedo reticularis), new or unexplained bruising, or wounds that are slow to heal, especially if you take hydroxyurea.
Nails: Note any new dark lines running lengthwise under the nail, which could be splinter hemorrhages.
General skin: Monitor for persistent itching without a visible rash, new dry patches or sun sensitivity (especially on treatment with interferon-alfa), or darkening of skin or nails (a known hydroxyurea effect).

Photographs taken in consistent lighting make it easier to track gradual changes over weeks and share them with your care team. A change that develops slowly over months can be invisible day to day but obvious when you compare two photos taken weeks apart. This is especially useful for monitoring livedo reticularis or the early stages of a potential hydroxyurea-related ulcer, both of which can begin subtly before becoming clinically significant.

1
PubMed Central. Secondary erythromelalgia – a case report –
2
PubMed. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera
3
Thrombosis and Haemostasis. Erythromelalgia in Essential Thrombocythemia Is Characterized by Platelet Activation and Endothelial Cell Damage but not by Thrombin Generation
4
PubMed. Erythromelalgia in thrombocythemia of various myeloproliferative disorders
5
PubMed. Essential Thrombocythemia: The Dermatologic Point of View
6
PubMed. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement
7
PubMed Central. Toe Gangrene as the First Presenting Symptom of Essential Thrombocythemia: A Case Report
8
PubMed Central. Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases
9
International Journal of Surgery Case Reports. Repairing of recurrent leg ulcer induced by hydroxyurea with posterior tibial artery perforator propeller flap: Case report
10
PubMed Central. Platelets in Kawasaki disease: Is this only a numbers game or something beyond?
11
PubMed Central. High Rate of Obstetric Complications in Patients With Essential Thrombocythemia